TRI-SOLFEN
Active Ingredient: BUPIVACAINE HYDROCHLORIDE, CETRIMIDE, EPINEPHRINE BITARTRATE, LIDOCAINE HYDROCHLORIDE MONOHYDRATE
Product Overview
About TRI-SOLFEN
TRI-SOLFEN is a topical anesthetic and antimicrobial solution, containing a combination of BUPIVACAINE HYDROCHLORIDE, CETRIMIDE, EPINEPHRINE BITARTRATE, and LIDOCAINE HYDROCHLORIDE MONOHYDRATE. It is designed for use in minor surgical procedures, skin biopsies, and other dermatological applications where local anesthesia and antimicrobial protection are required.
Key Benefits & Uses
- Provides effective local anesthesia for minor surgical procedures and skin biopsies
- Offers antimicrobial protection to prevent infection and promote wound healing
- Can be used in a variety of dermatological applications, including skin biopsies, minor surgical procedures, and wound care
Active Ingredient & Action
BUPIVACAINE HYDROCHLORIDE, the primary anesthetic component of TRI-SOLFEN, works by blocking nerve impulses in the skin, providing a temporary loss of sensation and pain relief. CETRIMIDE, an antimicrobial agent, helps to prevent infection and promote wound healing by inhibiting the growth of bacteria and other microorganisms. EPINEPHRINE BITARTRATE, a vasoconstrictor, helps to reduce bleeding and swelling at the application site. LIDOCAINE HYDROCHLORIDE MONOHYDRATE, another anesthetic component, enhances the anesthetic effect of BUPIVACAINE HYDROCHLORIDE.
Important Notes
TRI-SOLFEN should only be used under the guidance of a qualified healthcare professional. It is essential to follow the recommended dosage and application instructions carefully to avoid adverse effects. Patients with certain medical conditions, such as heart problems or allergies, should consult their doctor before using TRI-SOLFEN. As with any topical anesthetic, there is a risk of systemic toxicity if absorbed in large quantities. If you experience any unusual symptoms or side effects, seek medical attention immediately.
Visitor ratings
Help others by rating how useful this product page is.
No ratings yet — be the first.
